Earnings Call Summary | ImmunoPrecise Antibodies(IPA.US) Q3 2024 Earnings Conference
Earnings Call Summary | ImmunoPrecise Antibodies(IPA.US) Q3 2024 Earnings Conference
The following is a summary of the ImmunoPrecise Antibodies Ltd. (IPA) Q3 2024 Earnings Call Transcript:
以下是ImmunoPrecise Antibodies Ltd.(IPA)2024年第三季度業績電話會議記錄摘要:
Financial Performance:
財務業績:
ImmunoPrecise reported a Q3 2024 revenue of $6.2 million, a 20.3% increase year-over-year.
Year-to-date revenue reached $18.1 million, showing a 20% rise from fiscal 2023.
The company reduced its net loss to $2.9 million or $0.11 per share from the previous year's loss of $4.7 million, or $0.19 per share.
Cash balance at the end of Q3 2024 was $6.2 million, compared to $8.3 million in the previous year.
R&D expenses were approximately $1 million for the quarter, significantly lower than the previous year.
ImmunoPrecise報告稱,2024年第三季度收入爲620萬美元,同比增長20.3%。
今年迄今爲止的收入達到1,810萬美元,比2023財年增長了20%。
該公司的淨虧損從上一年的470萬美元或每股虧損0.19美元減少至290萬美元,合每股虧損0.11美元。
2024年第三季度末的現金餘額爲620萬美元,而去年同期爲830萬美元。
本季度的研發費用約爲100萬美元,大大低於上一年。
Business Progress:
業務進展:
ImmunoPrecise made significant operational improvements by integrating BioStrand technology into their workflows, enhancing both scientific and commercialization initiatives.
The company expanded their facilities in Utrecht, Victoria, and Oss, and noted a significant performance in the B Cell program.
Their subsidiary BioStrand developed an AI model, LENSai, which improves precision in drug discovery and disease research, while reducing R&D costs.
The company has been expanding their VHH lead generation and gradually becoming more data-driven, underlining continual innovation.
ImmunoPrecise continues to integrate steady CRO revenue growth with in-silico technologies.
Strategic partnerships with pharmaceutical companies strengthen their tech validation, with plans for more collaborations.
ImmunoPrecise通過將BioStrand技術集成到其工作流程中,加強了科學和商業化計劃,從而對運營進行了重大改進。
該公司擴建了在烏得勒支、維多利亞和奧斯的設施,並注意到B Cell項目取得了顯著的業績。
他們的子公司BioStrand開發了一種名爲LenSAI的人工智能模型,該模型提高了藥物發現和疾病研究的精度,同時降低了研發成本。
該公司一直在擴大其VHH潛在客戶群體,並逐漸變得更加以數據爲導向,這突顯了持續創新。
ImmunoPrecise繼續將穩定的CRO收入增長與芯片內技術相結合。
與製藥公司的戰略合作伙伴關係加強了他們的技術驗證,並計劃進行更多合作。
More details: ImmunoPrecise Antibodies IR
更多詳情: immunoPrecise 抗體 IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。